Publications by authors named "W Rhys-Williams"

Article Synopsis
  • Nasal carriers were split into two groups to receive either XF-73 nasal gel or a placebo, administered five times over approximately 24 hours before cardiac surgery.
  • Patients using XF-73 showed a significant reduction in bacteria levels after two doses, with a decrease of -2.2 log CFU/mL, while the placebo group had almost no reduction at -0.01 log CFU/mL.
  • Post-surgery, 46.5% of the XF-73 group required anti-staphylococcal antibiotics compared to 70% in the placebo group, indicating a significant reduction in post-operative antibiotic usage for those treated with XF-73 (p = 0.045).
View Article and Find Full Text PDF

XF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative with rapid, potent bactericidal properties and a low propensity for engendering bacterial resistance. It is being developed clinically for the decolonization of in the nasal cavity to prevent post-operative staphylococcal infections. This study reports the minimum inhibitory concentration (MIC) of XF-73 in comparison to 22 antibiotics against a panel of >2,500 clinical isolates composed of 16 different Coagulase-positive and -negative species from 33 countries.

View Article and Find Full Text PDF

Compared with antibiotics for treating bacterial infections, there are a limited number of antifungal agents. This is due to several factors, including the difficulties of identifying suitable antifungals that target the fungal cell without damaging host cells, and the reduced rates of diagnosis of fungal infections compared with those caused by bacteria. The problem of treating fungal infections is exacerbated by an increasing incidence of antifungal resistance among human fungal pathogens.

View Article and Find Full Text PDF

We studied 83 cardiac-surgery patients with nasal carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a nasal carriage reduction of 2.5 log with XF-73 compared to 0.

View Article and Find Full Text PDF

With increasing incidence of antimicrobial resistance, there is an urgent need for novel and effective antibacterials. Destiny Pharma plc have developed a series of porphyrin-based XF drugs, some with dual mechanisms of antibacterial action. An innate mechanism acts through binding to the outer bacterial membrane and a separate, light-activated, photodynamic (PD) mechanism, acts the generation of reactive oxygen species.

View Article and Find Full Text PDF